Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials.
暂无分享，去创建一个
V. Budach | J. Debus | H. Verheul | M. D. de Jonge | B. van Triest | E. Troost | S. Goel | P. Geertsen | M. Mau-Sørensen | P. Aftimos | B. Sarholz | G. Locatelli | J. Falkenius | M. V. van Bussel | D. Nielsen | M. Kuipers | M. Samuels